Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Research programme: anti-cancer immunotherapeutic oligonucleotides - Tekmira Pharmaceuticals

Next Previous
X
Search
Drug Profile

Research programme: anti-cancer immunotherapeutic oligonucleotides - Tekmira Pharmaceuticals

Alternative Names: INX-0167; INX-0204; OligoVax; TKM-0167

Latest Information Update: 16 Oct 2013

Price :

$50 *

Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Inex Pharmaceuticals Corporation
  • Developer Tekmira Pharmaceuticals Corporation
  • Class Antigens; Oligonucleotides
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Cancer
  • Discontinued Bacterial infections; Viral infections

Most Recent Events

  • 31 Dec 2012 No development reported - Preclinical for Cancer in Canada (Injection)
  • 02 Jul 2009 Preclinical development in Cancer is ongoing in Canada
  • 23 Jul 2004 Preclinical data from a media release have been added to the Cancer pharmacodynamics section

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top